Naltrexone/bupropion

Last updated

Naltrexone/bupropion
Bupropion and naltrexone.svg
Skeletal structures of bupropion (top) and naltrexone (bottom)
Combination of
Naltrexone Opioid receptor antagonist
Bupropion Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
Clinical data
Trade names Contrave, Mysimba
AHFS/Drugs.com Monograph
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
KEGG
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity. [4] [6] It contains naltrexone, an opioid antagonist, and bupropion, an aminoketone atypical antidepressant. [4] It is taken by mouth. [4] Both medications have individually shown some evidence of effectiveness in weight loss, and the combination has been shown to have some synergistic effects on weight. [7]

Contents

In September 2014, a sustained release formulation of the drug was approved for marketing in the United States under the brand name Contrave. [8] [9] The combination was subsequently approved in the European Union in the spring of 2015, where it is sold under the name Mysimba. [5] [10] It was approved in Canada under the Contrave brand name in 2018. [11]

Medical uses

Naltrexone/bupropion is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, as anti-obesity medication for the management of weight in adults with an initial body mass index (BMI) of: [4] [5]

Available forms

Each Contrave tablet contains 8 mg naltrexone and 90 mg bupropion. [12] Once full dosing is reached (after 4 weeks of administration), the total dosage of Contrave for treating overweight or obesity is two tablets twice daily or 32 mg naltrexone and 360 mg bupropion per day. [12]

Contraindications

According to the U.S. Food and Drug Administration (FDA), naltrexone/bupropion is contraindicated in patients who have/are: [4]

Adverse effects

The FDA has issued a boxed warning regarding an increased risk for suicidal thoughts and behavior in children, adolescents, and young adults under the age of 25. [4] This is attributed to the bupropion component, as the FDA requires all antidepressants to include that boxed warning on medication package inserts. [13]

The safety and effectiveness of Naltrexone/bupropion in children under the age of 18 has not been studied. [4]

Mechanism of action

Individually, naltrexone and bupropion each target pathways in the central nervous system that influence appetite and energy use.

Combined, naltrexone/bupropion affects the reward pathway which results in reduced food cravings. [15] In 2009, Monash University physiologist Michael Cowley was awarded one of Australia's top research honors, the Commonwealth Science Minister's Prize for Life Scientist of the Year, in recognition of his elucidation of these pathways, which led to the development of the combination medication. [16]

History

Orexigen submitted a New Drug Application (NDA) for the combination to the FDA in March 2010. [17] Having paid a fee under the Prescription Drug User Fee Act, Orexigen was given a deadline for the FDA to approve or reject the drug of January 2011. In December 2010, an FDA Advisory Committee voted 13-7 for the approval of Contrave and voted 11-8 for the conduct of a post-marketing cardiovascular outcomes study. [18] Subsequently, on 2 February 2011, the FDA rejected the drug and it was decided that an extremely large-scale study of the long-term cardiovascular effects of Contrave would be needed, before approval could be considered. [19] It was ultimately approved in the United States in 2014. [9]

In December 2014, the EU's Committee for Medicinal Products for Human Use (CHMP) endorsed the combination for licensure as an obesity medication when used alongside diet and exercise. [20] Approval was granted in March 2015. [10]

In May 2015, Orexigen prematurely ended the trial that was intended to test whether naltrexone/bupropion increased the risk of major adverse cardiovascular events in obese patients with cardiovascular disease because an independent panel of experts said that the drug maker “inappropriately” compromised the trial by prematurely releasing interim data. The early data release reported a reduction in heart attacks, but that advantage was no longer observed when a more complete view of the data was analyzed. [21] The company then initiated a second trial (CONVENE) designed to test this outcome in 2016, but it was terminated in 2016 shortly after Takeda announced that it would sell its rights to the drug in the USA to Orexigen. [22]

In 2018, Orexigen sold its assets, including Contrave, to Nalpropion Pharmaceuticals. [23] [24]

Society and culture

Economics

The sustained-release formulation, Contrave, is marketed by Takeda under license from the combination medication's developer, Orexigen Therapeutics. [9] As of 2015, Orexigen received 20% of net sales from Takeda. [25]

Related Research Articles

<span class="mw-page-title-main">Naloxone</span> Opioid receptor antagonist

Naloxone is an opioid antagonist: a medication used to reverse or reduce the effects of opioids. For example, it is used to restore breathing after an opioid overdose. It is also known as Narcan. Effects begin within two minutes when given intravenously, five minutes when injected into a muscle, and ten minutes as a nasal spray. Naloxone blocks the effects of opioids for 30 to 90 minutes.

<span class="mw-page-title-main">Bupropion</span> Medication mainly used for depression and smoking cessation

Bupropion, formerly called amfebutamone, and sold under the brand name Wellbutrin among others, is an atypical antidepressant primarily used to treat major depressive disorder, seasonal affective disorder and to support smoking cessation. It is also popular as an add-on medication in the cases of "incomplete response" to the first-line selective serotonin reuptake inhibitor (SSRI) antidepressant. Bupropion has several features that distinguish it from other antidepressants: it does not usually cause sexual dysfunction, it is not associated with weight gain and sleepiness, and it is more effective than SSRIs at improving symptoms of hypersomnia and fatigue. Bupropion, particularly the immediate release formulation, carries a higher risk of seizure than many other antidepressants, hence caution is recommended in patients with a history of seizure disorder. The medication is taken by mouth.

<span class="mw-page-title-main">Venlafaxine</span> Antidepressant medication

Venlafaxine, sold under the brand name Effexor/Efexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Studies have shown that venlafaxine improves post-traumatic stress disorder (PTSD). It may also be used for chronic neuropathic pain. It is taken orally. It is also available as the salt venlafaxine besylate in an extended-release formulation.

An anorectic is a drug which reduces appetite, resulting in lower food consumption, leading to weight loss. These substances work by affecting the central nervous system or certain neurotransmitters to create a feeling of fullness or reduce the desire to eat. The understanding of anorexiant effects is crucial in the development of interventions for weight management, eating disorders, and related health concerns. The anorexiant effect can be induced through diverse mechanisms, ranging from hormonal regulation to neural signaling. Ghrelin, leptin, and peptide YY are among the hormones involved in appetite control. Additionally, neurotransmitters such as serotonin and dopamine in the central nervous system contribute significantly to the regulation of food intake.

<span class="mw-page-title-main">Buprenorphine</span> Opioid used to treat pain & opioid use disorder

Buprenorphine, sold under the brand name Subutex among others, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It can be used under the tongue (sublingual), in the cheek (buccal), by injection, as a skin patch (transdermal), or as an implant. For opioid use disorder, the patient must have moderate opioid withdrawal symptoms before buprenorphine can be administered under direct observation of a health-care provider.

<span class="mw-page-title-main">Anti-obesity medication</span> Class of pharmacological agents

Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of the human body, weight regulation, by: reducing appetite and consequently energy intake, increasing energy expenditure, redirecting nutrients from adipose to lean tissue, or interfering with the absorption of calories.

<span class="mw-page-title-main">Naltrexone</span> Medication

Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. It has also been found effective in the treatment of other addictions and may be used for them off-label. An opioid-dependent person should not receive naltrexone before detoxification. It is taken orally or by injection into a muscle. Effects begin within 30 minutes, though a decreased desire for opioids may take a few weeks to occur.

<span class="mw-page-title-main">Sitagliptin</span> Diabetes medication

Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes. In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea. It is taken by mouth. It is also available in the fixed-dose combination medication sitagliptin/metformin.

<span class="mw-page-title-main">Lofexidine</span> Medication used for opioid withdrawal

Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure; today, it is more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A-adrenergic receptor agonist. It was approved for use by the Food and Drug Administration in the United States in 2018.

<span class="mw-page-title-main">Nalmefene</span> Opioid antagonist

Nalmefene, sold under the brand name Revex among others, is a medication that is used in the treatment of opioid overdose and alcohol dependence. Nalmefene belongs to the class of opioid antagonists and can be taken by mouth, administered by injection, or delivered through nasal administration.

<span class="mw-page-title-main">Lorcaserin</span> Antiobesity drug

Lorcaserin, marketed under the brand name Belviq, was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating serotonin receptor the 5-HT2C receptor in the hypothalamus, a region of the brain which is known to control appetite. It was approved in 2012, and in 2020, it was removed from the market in the United States due to an increased risk of cancer detected in users of Belviq.

<span class="mw-page-title-main">Vilazodone</span> Antidepressant medication

Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. It is classified as a serotonin modulator and stimulator and is taken by mouth.

Michael Cowley is an Australian physiologist. He is best known for his mapping of the neural circuits involved in metabolism and obesity and diabetes treatment. He is a professor in the Department of Physiology at Monash University in the Faculty of Biomedical and Psychological Sciences. He is also a director of the Australian diabetes drug development company, Verva Inc, and director of the Monash Obesity & Diabetes Institute] (modi).

The drug combination morphine/naltrexone is an opioid combination pain medication developed by King Pharmaceuticals for use in moderate to severe pain. The active ingredients are morphine sulfate and naltrexone hydrochloride; morphine being an opioid receptor agonist and naltrexone an opioid receptor antagonist. It is a schedule II controlled substance, and is intended for long-term pain caused by malignancy or where lower tiers of the pain management ladder have already been exhausted, and where medications such as oxycodone would otherwise have been indicated.

<span class="mw-page-title-main">Bupropion/zonisamide</span> Combination drug

Bupropion/zonisamide is an experimental combination of bupropion which was under development for the treatment of obesity. Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor. The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.

<span class="mw-page-title-main">Phentermine/topiramate</span> Obesity medication

Phentermine/topiramate, sold under the brand names Qsymia or QSIVA, is a combination drug of phentermine and topiramate used to treat obesity. It is used together with dietary changes and exercise. If less than 3% weight loss is seen after 3 months it is recommended the medication be stopped. The weight loss is modest. Effects on heart related health problems or death is unclear.

<span class="mw-page-title-main">Setmelanotide</span> Chemical compound

Setmelanotide, sold under the brand name Imcivree, is a medication used for the treatment of genetic obesity caused by a rare single-gene mutation.

<span class="mw-page-title-main">Dextromethorphan/bupropion</span> Combination medication

Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD). Its active components are dextromethorphan (DXM) and bupropion. Patients who stayed on the medication had an average of 11% greater reduction in depressive symptoms than placebo in an FDA approval trial. It is taken as a tablet by mouth.

Empagliflozin/metformin, sold under the brand name Synjardy among others, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It contains empagliflozin and metformin hydrochloride. It is taken by mouth.

References

  1. ↑ "Regulatory Decision Summary — Contrave". Health Canada. 23 October 2014. Archived from the original on 4 December 2020. Retrieved 7 June 2022.
  2. ↑ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada . 14 October 2020. Archived from the original on 17 April 2024. Retrieved 17 April 2024.
  3. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  4. 1 2 3 4 5 6 7 8 9 10 "Contrave Extended-Release- naltrexone hydrochloride and bupropion hydrochloride tablet, extended-release". DailyMed. 26 April 2019. Archived from the original on 4 June 2020. Retrieved 5 August 2020.
  5. 1 2 3 4 5 "Mysimba EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 22 October 2020. Retrieved 5 August 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  6. ↑ Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, St Jeor S (April 2009). "Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity". Expert Opinion on Pharmacotherapy. 10 (6): 1069–81. doi:10.1517/14656560902775750. PMID   19364254. S2CID   56625956.
  7. ↑ Tek C (2016). "Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives". Patient Preference and Adherence. 10: 751–9. doi: 10.2147/PPA.S84778 . PMC   4862388 . PMID   27217728.
  8. ↑ "Drug Approval Package: Contrave (naltrexone hydrochloride/bupropion hydrochloride) Extended-Release Tablets NDA #200063". U.S. Food and Drug Administration (FDA). 12 November 2014. Archived from the original on 4 June 2020. Retrieved 5 August 2020.
  9. 1 2 3 "FDA approves weight-management drug Contrave" (Press release). FDA. 10 September 2014. Archived from the original on 17 February 2017. Retrieved 16 December 2019.
  10. 1 2 Orexigen Therapeutics, Inc. (26 March 2015). "Orexigen's Mysimba Approved in Europe for the Treatment of Obesity". Yahoo! Finance. PR Newswire. Archived from the original on 31 March 2015. Retrieved 28 March 2015.
  11. ↑ "Regulatory Decision Summary — Contrave — Health Canada". Health Canada . 13 February 2018. Archived from the original on 4 December 2020. Retrieved 5 September 2021.
  12. 1 2 "CONTRAVE (naltrexone HCl and bupropion HCl)" (PDF). Archived (PDF) from the original on 2 October 2021. Retrieved 10 July 2024.
  13. ↑ "Suicidality in Children and Adolescents Being Treated With Antidepressant Medications". United States Food and Drug Administration. 3 November 2018. Archived from the original on 23 August 2020. Retrieved 21 February 2024.
  14. ↑ Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. (January 2009). "Rational design of a combination medication for the treatment of obesity". Obesity. 17 (1): 30–9. doi: 10.1038/oby.2008.461 . PMID   18997675. S2CID   24856014.
  15. ↑ Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. (May 2013). "A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)". Obesity. 21 (5): 935–43. doi:10.1002/oby.20309. PMC   3739931 . PMID   23408728.
  16. ↑ "Obesity expert named Life Scientist of the Year". Monash University. 29 October 2009. Archived from the original on 2 November 2009.
  17. ↑ "Orexigen Therapeutics Submits Contrave New Drug Application to FDA for the Treatment of Obesity" (Press release). Orexigen Therapeutics. Archived from the original on 25 April 2023. Retrieved 2 July 2024– via PR Newswire.
  18. ↑ "Press Release". Orexigen Therapeutics, Inc. 7 December 2010. Retrieved 29 December 2016.[ permanent dead link ]
  19. ↑ Contrave Archived 30 December 2016 at the Wayback Machine , Drugs.com
  20. ↑ "Orexigen's weight-loss drug gets thumbs-up from CHMP". Fierce Pharma. 19 December 2014. Archived from the original on 30 December 2016. Retrieved 29 December 2016.
  21. ↑ Silverman E (12 May 2015). "Orexigen Study for Diet Drug Ends Over Premature Data Disclosure". WSJ. Archived from the original on 30 December 2016. Retrieved 29 December 2016.
  22. ↑ O'Riordan M (14 April 2016). "Another CV Outcomes Trial Testing Weight-Loss Drug Contrave Terminated Early". TCTMD . Cardiovascular Research Foundation. Archived from the original on 20 May 2024. Retrieved 20 May 2024.
  23. ↑ "Orexigen, seller of weight-loss drug Contrave, agrees to sale for $75 million". San Diego Union-Tribune. 23 April 2018. Archived from the original on 13 October 2018. Retrieved 5 August 2020.
  24. ↑ "Nalpropion Pharmaceuticals, Inc. Expands Agreement with iNova Pharmaceuticals for Exclusive Commercialization Rights for Contrave (naltrexone HCl / bupropion HCl extended-release) to include Select Markets in Southeast Asia, Africa and the Pacific" (Press release). Nalpropion Pharmaceuticals. 19 December 2018. Archived from the original on 28 October 2021. Retrieved 5 August 2020– via GlobeNewswire.
  25. ↑ Osborne S (8 May 2015). "Orexigen Posts Loss — Revenue Will Be The Story". Seeking Alpha (blog). Archived from the original on 10 May 2015. Retrieved 9 May 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.